



## Formulary Update

## MANITOBA

Teva Canada is pleased to announce that the following products will be listed on the Manitoba Drug Benefits and Interchangeability Formulary effective June 1, 2022.

Product Name	Strength	Size	ltem Number	DIN
Octreotide for Injectable Suspension	10 mg	8 mL, Vial	65409-0001	02503751
Octreotide for Injectable Suspension	20 mg	8 mL, Vial	65410-0001	02503778
Octreotide for Injectable Suspension	30 mg	8 mL, Vial	65411-0001	02503786

To obtain additional information, please contact your local Teva Canada Representative or Customer Care at 1.800.268.4129

TevaCanada.com